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Abstract
Summary We completed a systematic review of the literature
to examine the impact of pharmacist interventions in
improving osteoporosis management. Results from random-
ized controlled trials suggest that pharmacist interventions
may improve bone mineral density testing and calcium intake
among patients at high risk for osteoporosis.
Introduction Pharmacists play a key role in many healthcare
systems by helping patients manage chronic diseases. We
completed a systematic review of the literature to identify
randomized controlled trials (RCTs) that have examined the
impact of pharmacy interventions in narrowing two gaps in
osteoporosis management: identifying at-risk individuals and
improving adherence to therapy.
Methods We searched the electronic databases of EMBASE,
HealthStar, International Pharmaceutical Abstracts,M E D -
LINE, and PubMed from database development to April
2010, examined grey literature, and completed manual
searches of reference lists to identify English-language
research that examined osteoporosis management interven-
tions within pharmacy practice. Results from RCTs were
abstracted and assessed for bias.
Results We identified 25 studies that examined pharmacist
interventions in osteoporosis management: 16 cohort, 5 cross-
sectional, 1 historical/ecological control, and 3 RCTs. RCT
interventions included osteoporosis educational and counsel-
ing programs, screening by pharmacists based on risk factor
assessment or bone mineral density testing, and physician
contact or recommendations for patients to follow-up with a
general practitioner. Results from the three RCTs suggest that
pharmacist interventions may improve bone mineral density
testing (targeted screening) and calcium intake among patients
at high risk for osteoporosis. However, two of the three RCTs
had high risk of bias, and no study examined the impact of
pharmacist intervention on osteoporosis treatment adherence.
Conclusions Data support the potential role for pharmacists
to help reduce gaps in osteoporosis management through
improved identification of high-risk patients. More research
is needed to examine pharmacist interventions on osteopo-
rosis treatment adherence.
Keywords Osteoporosis.Outcome assessment.
Pharmacists.Review.Systematic
Introduction
Two gaps in osteoporosis management are well documented:
(1) most patients at high risk for fracture are not identified for
treatment, and (2) adherence to osteoporosis pharmacotherapy
is suboptimal [1–3]. For example, post-fracture osteoporosis
screening and treatment rates are below 20% in most settings
[1, 4], and approximately half of the patients who start
osteoporosis pharmacotherapy discontinue treatment within
the first year of therapy [2, 3]. In theory, pharmacists may play
a role in narrowing gaps in osteoporosis diagnosis and
treatment adherence. First, pharmacists may help identify
high-risk patients, such as those on chronic glucocorticoid
therapy who can then be targeted for bone mineral density
(BMD) testing and treatment initiation. Second, pharmacists
can provide counseling and educate patients on medication
use, fall prevention, and the importance of calcium, vitamin
D, exercise, and adherence to therapy. A recent review
identified that non-drug interventions by healthcare profes-
sionals improved quality of life, treatment adherence, and
calcium intake among community-dwelling postmenopausal
women with osteoporosis; however, no study within the
review examined pharmacist interventions [5]. We therefore
completed a systematic review of the literature to identify all
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interventions in osteoporosis management. The purpose of
our review was to use results from randomized controlled
trials (RCTs) to determine if pharmacy interventions can help
narrow two gaps in osteoporosis management: identifying at-
risk individuals and improving adherence to therapy.
Methods
Data sources and study eligibility
The electronic databases EMBASE, HealthStar, International
Pharmaceutical Abstracts, MEDLINE, and PubMed were
searched from database development to April 2010 to identify
all English language publications that examined pharmacist
interventions in osteoporosis management. Search terms were
adaptedfromaCochraneCollaborationreview[6] and selected
upon consultation with a library scientist, Appendix Table 4.
Any intervention that utilized a pharmacist to improve
osteoporosis management was eligible. Manual searches of
reference lists from eligible studies and a grey literature search
were also completed [7, 8]. Our grey literature search targeted
government, research institution, professional association, and
osteoporosis foundation websites to try to capture research
published as a report and not accessible through traditional
research databases, Appendix Table 5. Abstracts, commentar-
ies, letters, news articles, and review papers were excluded.
Titles and abstracts were reviewed for relevance by two
authors (MNE, AMB), and discrepancies were settled through
consultation with a third author (SMC). All relevant publica-
tions were identified, yet only RCTs were eligible for detailed
review. We therefore identified all papers that included a
pharmacist in the context of osteoporosis management, yet
focused on RCTs as these may provide the highest quality of
evidence [8].
RCT data abstraction
Study characteristics including research design, setting,
pharmacist training, patient inclusion criteria, patient recruit-
ment, intervention details, and outcomes were abstracted by
two authors (MNE, AMB) and confirmed by a third author
(SMC).Sincetheultimategoalofidentifyinghigh-riskpatients
is treatment to reduce fracture risk, our a priori focus was on
process of care outcomes related to improved identification of
at-riskindividuals(e.g.,BMDtestingandphysicianfollow-up)
and osteoporosis treatment initiation. We had intended to
examine the impact of pharmacist interventions on osteoporo-
sis treatment adherence; however, no relevant study was
identified. After the identification of relevant literature, we
decided to summarize information concerning improvements
in calcium and vitamin D intake or supplementation.
Qualitative assessment of risk of bias
We qualitatively examined the threats to internal validity for
each trial based on risk for allocation bias, attrition bias,
detection bias, and performance bias [8, 9]. Following recent
guidelines to improve terminology in non-experimental
research [10], we grouped these four potential biases into
two types: (1) selection bias, related to allocation and attrition,
and (2) information bias, related to detection and performance.
Allocation bias occurs when randomization fails such that
comparison groups differ on important prognostic variables.
Attrition bias occurs when patients who continue to be
followed are systematically different from those who are lost
to follow-up in ways that impact outcomes. Detection and
performance biases are classified as different types of
information bias—biases that occur when there are systematic
differences in the completeness or accuracy of data that lead to
differential misclassification of patient characteristics, expo-
sure, or outcomes [10]. Detection bias results from differential
outcome assessment between comparison groups, and perfor-
mance bias results from unequal provision of care between
comparison groups other than differences related to the main
intervention [9]. We then classified the level of risk of bias
based on whether there was little evidence that the bias would
impact study results (low) or if some evidence suggested that
the bias may have impacted study results (high). We did not
use a more fine assessment to identify medium risk of bias.
Results
Of the 611 unique English language publications identified
from the database searches, 118 were pulled for detailed review
andoneadditionalpublication[11] was found from the manual
search of reference lists, Fig. 1. No grey literature was
identified. Of the 119 publications reviewed, 25 examined
pharmacist interventions in osteoporosis management: 16
cohort [12–27], five cross-sectional [28–32], one historical/
ecological control [33], and three RCTs [34–36]. Of the three
RCTs, two were cluster RCTs that involved the randomization
of pharmacies/pharmacists rather than randomization of single
patients [34, 35]. Characteristics of the three RCTs are
summarized in Table 1, and potential biases are summarized
in Table 2.
1. Cluster RCT in Australia
Crockett et al. completed a cluster RCT in New South Wales,
Australia whereby all 86 community pharmacists in six
suburb and six rural communities were invited to participate
[34]. Of the pharmacists that were willing and had suitable
space and staffing to participate, one pharmacist within each
of the six suburban and six rural areas was randomly selected
2588 Osteoporos Int (2011) 22:2587–2596for participation. Each of the 12 randomly selected pharma-
cists was then randomized into one of two groups: (1) non-
BMD group, pharmacists offered education, counseling, and
risk assessment based on patient questionnaire responses only
and (2) BMD group, pharmacists offered education, counsel-
ing, and risk assessment based on questionnaire responses and
forearm BMD test results. The forearm BMD tests were
performed by a radiographer using peripheral dual-energy X-
ray absorptiometry (DXA). All 12 participating pharmacists
were provided with an information package and invited to
attend a 7-h training session or receive an on-site training
visit. After pharmacist training, the chief research officer and
project officer visited study sites to ensure adherence to
protocol and service delivery consistency. Each pharmacist
was asked to recruit 20 participants meeting eligibility criteria
(Table 1). Participants deemed to be at medium or high risk
based on questionnaire (non-BMD group) or questionnaire
and BMD (BMD group) were advised to see a general
practitioner. Outcomes were assessed by telephone follow-up
at 3 and 6 months post-intervention. The outcomes of interest
for our review included patient self-report of pharmacist
recommendations (increase in calcium or vitamin D intake
and need for follow-up with a general practitioner), and
whether or not the patient followed through with baseline
recommendations given by the pharmacist.
The internal validity of this tri a li sl i m i t e dw i t hh i g hr i s ko f
bias across all four levels evaluated, Table 2. First, we note
potential selection bias related to allocation: patients self-
referred into the study and there was a significant difference in
recruitment success between the rural non-BMD (n=43 of 60
target) and rural BMD (n= 6 0o f6 0t a r g e t )p h a r m a c i e s ;a n d
attrition: although 87% of participants responded at 3 months,
only 20 (10%) patients in total were contacted at 6 months
[34]. In addition, the 6-month follow-up was targeted to those
deemed at high risk at baseline, yet baseline risk assessment
was differential between groups (performance bias). Finally,
potential detection bias is high with outcomes based on
patient self-report and the patient’s ability to recall pharmacist
recommendations. Despite limitations and documentation of
little difference in study outcomes in terms of physician
follow-up or calcium/vitamin D intake (Table 3), the study
found significantly better patient satisfaction after 3 months of
follow-up among those provided with the intervention that
included forearm BMD testing (90% satisfied), compared to
those with the educational intervention that did not include
BMD measurement (67% satisfied) [34].
2. Cluster RCT in USA
McDonough et al. completed a cluster RCT of 15
community pharmacies (eight intervention, seven control)
in Iowa, USA [35]. These pharmacies were part of a
specialized provider network consisting of pharmacists with
previous training and/or certification in drug therapy
monitoring and research participation. All pharmacists in
the participating pharmacies received approximately 4 h of
training related to glucocorticoid-induced osteoporosis and
were provided with a package of articles for independent
study. Pharmacists within each pharmacy then used dis-
pensing records to identify and mail invitation letters to
eligible patients (aged ≥18 years with the equivalent of
7.5 mg or more of prednisone for ≥6 months). Pharmacies
in the control group provided “usual and customary care”
to participants. Intervention group pharmacies provided
Articles excluded (n=493)  
￿ title (n=403) 
￿ abstract (n=90) 
Identified from reference lists (n=1) 
Articles excluded after content analysis (n=94) 
￿ abstracts/conference proceedings (n=15) 
￿ notes/summaries (n=12) 
￿ no primary data collection (n=14) 
￿ did not meet inclusion/exclusion criteria (n=37)
￿ not located (n=9) 
￿ not in English (n=3) 
￿ other (n=4)
Duplicates removed (n=461) 
Distinct articles identified (n= 611)
Ovid  
EMBASE 
(n= 315) 
Ovid 
HealthStar 
(n=178) 
Ovid
IPA
(n=200)
Ovid 
MEDLINE  
(n= 261)
Articles identified via electronic search (n=1072)*
Eligible studies from electronic search (n=118)
PubMed 
(n= 118) 
Articles identified (n=25)
RCTs (n=3)
Eligible studies identified (n=119)
Fig. 1 Flow chart of literature
search strategy. IPA International
Pharmaceutical Abstracts.
*no grey literature identified
from our primary search
(Appendix Table 5)
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2590 Osteoporos Int (2011) 22:2587–2596patients with: an information pamphlet about glucocorticoid-
inducedosteoporosis,education,anddrugtherapymonitoring.
In addition, each participant’s prescribing physician was
mailedastandardizedcommunicationexplainingtheprogram,
their patient’s inclusion and any therapeutic problems identi-
fied. Study outcomes were assessed by web survey completed
in the participating pharmacies at 9 months post-intervention.
The outcomes of interest included change from baseline in
bisphosphonate treatment, calcium supplementation, and
DXA testing.
Overall risk of bias in this trial is high based on allocation
and attrition (selection bias). First, we note potential
allocation bias with significantly fewer participants enrolled
in the control group (n=26) compared to the intervention
group (n=70), and participants in the intervention group had
higher baseline fracture risk: 74% intervention vs. 58%
control were female, and 30% intervention vs. 12% control
had a prior fracture; and prior osteoporosis management:
52% intervention vs. 24% control had a DXA test, and 17%
intervention vs. 0% control used bisphosphonates at baseline.
Table 2 Summary of potential risk of bias based on threats to internal validity
Study Selection Bias Information Bias
Allocation
a Attrition
b Performance
c Detection
d
Crockett
et al. [34]
High High High High
￿ Better recruitment
success in BMD group
in rural regions (n=60
vs. n=43)
￿ 3-month follow-up, 87% ￿ Definition of risk
differed between
groups
￿ Self-report assessment based on
patient recall of pharmacist
recommendations and whether
or not they complied with the
pharmacist’s recommendations ￿ Non-BMD group had
larger proportion with
history of low-trauma
fracture (21% vs. 11%)
￿ 6-month follow-up, 10%;
only “high-risk” followed
￿ Group 1:
questionnaire only
￿ Group 2:
questionnaire and
forearm BMD results
McDonough
et al. [35]
High High Low Low
￿ Significantly more
participants in
intervention vs.
control (n=70 vs.
n=26)
￿ Follow-up: ￿ Little evidence that the
“usual care” group
differed outside
the intervention
￿ Although outcomes are based on
self-report, evidence suggests
that self-report of DXA testing
and bisphosphonate use is very
good [49, 50]
￿ Intervention group
at higher risk, e.g.:
￿ 87% intervention
￿ All participating
pharmacists had
training or certification
in research participation a. Female (74%
vs. 58%)
￿ 73% control
b. Fracture history
(30% vs. 12%)
Y uksel
et al. [36]
Low Low Low Low
￿ Intervention group
had significantly
more participants
with family history
of OP (47% vs. 34%)
￿ Attrition: n=26 (20%) in
intervention and n=23
(17%) in control
￿ All participating
pharmacists received
training
￿ Self-report confirmed by DXA
report from physician (test
performed) and pharmacy
records (prescription dispensed)
￿ However, analyses
adjusted for age, sex,
and family history of OP
￿ However, all were
accounted for in
the analyses (intention
to treat analysis)
￿ Control (“usual care”)
group also given
educational material,
and thus, the effect may
be larger than what was
observed in the trial
when compared
to true “usual care”
Low risk of bias means that there is little evidence that this type of bias impacted study results. High risk of bias means that some evidence
indicates that this type of bias may have impacted study results
BMD bone mineral density group (peripheral DXA), DXA dual-energy X-ray absorptiometry, OP osteoporosis
aAllocation bias occurs when randomization fails such that comparison groups differ on important prognostic variables
bAttrition bias may occur if patients who continue to be followed are systematically different from those who are lost to follow-up in ways that
effect outcomes
cPerformance bias results from differences in the provision of care between comparison groups other than differences that relate to the main
intervention
dDetection bias results from differential outcome assessment between comparison groups
Osteoporos Int (2011) 22:2587–2596 2591Second, attrition bias is relevant with only 61 participants in
the intervention group (87%) and 19 participants in the
control group (73%) after exclusions based on missing data.
Therefore, although this trial documented significant
improvements in calcium intake from baseline in the
intervention group (+17%) compared to the control group
(−7%) [35], and smaller increase in DXA testing (+20%
intervention vs. +39% control), it is possible that the
differences result from selection bias introduced in the trial.
3. RCT in Canada
Y uksel et al. completed an RCT within 15 Save on Foods
community pharmacies in Alberta, Canada [36]. Patients
who met eligibility based on risk for osteoporosis (Table 1)
and who signed informed consent were randomized using a
secure internet randomization service into two groups:
control or intervention. Participants in the intervention group
received oral and written education about their risks for
osteoporosis, had BMD measured by heel quantitative
ultrasound (QUS), and were counseled regarding their risks
for osteoporosis during a 30 minute session with the
pharmacist. Intervention patients were also encouraged to
follow-up with their primary care physician, and physicians
were informed about their patient’s study enrolment, QUS
results, and eligibility for central DXA testing. Participants
in the control group received usual care and print material
from Osteoporosis Canada. The primary outcome was a
composite of DXA test and/or new osteoporosis treatment
initiation at 4 months post-intervention. Self-report of the
primary outcome was confirmed by physician contact (copy
of DXA report) and pharmacy dispensing records (initiation
of new osteoporosis medication). Secondary outcomes in-
cluded daily calcium and vitamin D intake.
Despite randomization, a larger proportion of patients in the
intervention group reported a family history of osteoporosis
(47% vs. 34%, p=0.03), and although not statistically
significant, we note a larger proportion in the intervention
group were white (66% vs. 56%) and were current smokers
(17% vs. 9%) [36]. Nonetheless, authors appropriately
adjusted for important baseline risk factors for osteoporosis
in their analysis, including age, sex, and family history of
osteoporosis. We therefore document low risk of bias related
to allocation. Similarly, although 49 patients were lost to
follow-up after allocation (26 intervention, 23 control), all
were appropriately included in the analysis, minimizing
potential attrition bias. We classify the risk of detection bias
as low because self-report of the primary outcome was
confirmed by physician contact and pharmacy dispensing
records. Although we document low risk for performance
Table 3 Measured outcomes in randomized controlled studies of pharmacy interventions in osteoporosis management
Study Follow-up details Outcomes measured Group 1 Group 2
n % n %
Non-BMD, n=84 BMD, n=114
Crockett et al. [34] 3-month telephone follow-up
(patient self-report)
Physician follow-up 2/7 28.6 3/22 13.6
Increase in calcium intake 37/45 82.2 29/38 76.3
Increase in vitamin D intake 18/21 85.7 4/7 57.1
Control, n=19 Intervention, n=61
McDonough et al. [35] 9-month
a web survey in pharmacy
(patient self-report)
DXA test – 39.2 – 19.6*
Bisphosphonate therapy – 10.5 – 9.1
Calcium supplementation – −6.9 – 17.1*
Control, n=133 Intervention, n=129
Y uksel et al. [36] 16 weeks, patient self-report in
pharmacy (confirmed by DXA
report and pharmacy dispensing
records)
Primary outcome
DXA test or OP treatment 14 10.5 28 21.7*
Secondary outcomes
DXA test 13 9.8 28 21.7*
New osteoporosis treatment 3 2.3 6 4.7
Additional patients meeting:
Calcium requirements 25 18.8 39 30.2*
Vitamin D requirements 22 16.5 24 18.6
BMD bone mineral density group (peripheral DXA), DXA dual-energy X-ray absorptiometry, OP osteoporosis
*p<0.05
aPercent change reported (from baseline to 9 months), calculated based on numbers presented in the paper. At baseline: 24% control vs. 52%
intervention had a DXA test, and 0% control vs. 17% intervention used bisphosphonates
2592 Osteoporos Int (2011) 22:2587–2596bias, we note that the effects of the intervention may be larger
in comparison to usual care in the “real-world,” since the trial
provided the control (usual care) group with information from
Osteoporosis Canada. Results from this robust trial found that
the pharmacist intervention increased DXA testing (22%
intervention, 10% control) and improved calcium intake (30%
intervention, 19% control) at 4 months follow-up, Table 3.
Discussion
Pharmacistsplayakeyroleasdrugexpertsinmanyhealthcare
systems. Over the last 20 years, the pharmacist’sr o l ei nm a n y
settings has shifted in focus from drug dispensing to patient-
centered pharmaceutical care [37, 38]. Pharmacist interven-
tions such as patient counseling, education, medication
management, and referrals to other healthcare professionals
have led to significant improvements in blood glucose levels
among diabetic patients, blood pressure levels among
antihypertensive patients, and cholesterol levels among
hyperlipidemic patients [39–41]. From our review, we found
that compared to “usual care,” a pharmacist intervention that
included patient counseling, education, QUS, and physician
contact increased central DXA testing and calcium intake
among individuals at high risk for osteoporosis. Although
not specifically identified within the studies included in our
review, a recent RCT identified that DXA testing among
women aged 45–54 years significantly increased the use of
osteoporosis pharmacotherapy and supplementation with
calcium and vitamin D [42] .F u r t h e rr e s e a r c hi sn e e d e dt o
determine if pharmacy interventions may also improve
osteoporosis treatment initiation.
Result from studies included in our review support the use
of heel QUS measurement as a feasible BMD screening
method that can be utilized by pharmacists [36]. Although
QUS is no better than questionnaires based on simple risk
factors, such as age, body weight, and sex in predicting those
likely to have low BMD [43], offering a clinical service such
as BMD measurement may be important for the success of
pharmacy-led osteoporosis interventions. In fact, one of the
trials included in our review that compared patient satisfac-
tion between two different pharmacist interventions found
that peripheral BMD testing was important for patient
recruitment and satisfaction [34]. Further research is needed
to clarify the importance of BMD measurement on the
success of community-based osteoporosis interventions.
Our study has many strengths, including a thorough
systematic search of the literature, having two independent
reviewers search for an abstract data and having a third
author to resolve discrepancies. We also focused on RCT
study designs. Nonetheless, our results are limited to the
quality and generalizability of the RCTstudies identified. In
fact, due to high risk of bias in two of the RCTs under
review, non-experimental studies may have yielded similar
quality results. If no plan exists to disseminate interventions
outside a local setting, lower-quality evidence may be
acceptable in quality improvement [44]. Evidence from
non-experimental studies may thus be informative for local
quality improvement interventions.
Our study is also limited by qualitative assessment of risk of
bias, which we ascribed as low or high risk based on our
assessment of whether or not evidence existed to suggest that
results may be biased.We had originally considered two quality
assessment tools [45, 46] used in prior reviews of pharmacist
interventions [8, 39–41]. However, upon the application of
these quality assessment tools, we found that neither
differentiated between the studies well. The first largely
focused on the quality of reporting methods [45], and we
found the second to be more relevant to drug interventions
than healthcare interventions [46]. We therefore decided to
examine the risk of bias qualitatively grouped under the main
headings of information bias and selection bias, and ascribed
“low risk” when we noted little evidence of potential bias, and
“high risk” when we noted some evidence of potential bias.
Further work to provide better quality assessment tools for
healthcare interventions is needed.
Although our findings suggest that community pharmacist
interventions may help to improve the identification of
individuals at risk for osteoporosis through improved DXA
testing, further study is important to determine the feasibility
of interventions in community pharmacies. We note that the
two trials with positive findings were completed in: (1) a
network of pharmacies that had pharmacists with advanced
training and experience in research participation [35] and (2)
community pharmacies within the same pharmacy chain
[36]. In addition, the one other RCT included in our review
had excluded pharmacies deemed to have too few staff or
insufficient space [34]. Therefore, the generalizability and
feasibility to other settings need to be explored. We also note
that none of the studies examined the impact of the
pharmacist interventions on osteoporosis treatment adher-
ence or considered pharmacists’ experience or satisfaction
with the osteoporosis management programs. Recent reviews
of the literature identify that strategies that enhance patient
and healthcare provider communication and treatment
follow-up may be key to improving adherence to osteopo-
rosis pharmacotherapy [5, 47, 48]. Further study is thus
important to identify the impact of pharmacy interventions
on treatment initiation and adherence to therapy, as well as to
examine the feasibility of osteoporosis management in
community pharmacy. Interventions in osteoporosis manage-
ment by physicians, physiotherapists, nurses, dieticians, and
other healthcare professionals working in teams have helped
to improve treatment adherence and calcium intake among
community-dwelling women [5] and increase BMD testing
and osteoporosis treatment rates in patients post-fracture [4].
Osteoporos Int (2011) 22:2587–2596 2593Conclusions
Pharmacists are in a unique position to help reduce the burden
of osteoporosis by improving the identification of high-risk
patients for treatment, especially those on corticosteroid
therapy. Results from our review suggest that pharmacist
identification and counseling of patients at risk for osteoporosis
results in higher DXA testing and improvements in calcium
intake. Furtherhigh-quality evidenceisneededtodeterminethe
feasibility of osteoporosis management in pharmacy practice
settings, to examine the comparative effectiveness of different
pharmacy intervention strategies, and to address the impact of
pharmacist interventions on osteoporosis treatment adherence.
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Table 4 Search strategy for MEDLINE, EMBASE, IPA, and HealthStar done April 20, 2010
Search Terms Ovid MEDLINE
a Results Ovid EMBASE
b Results Ovid IPA
c Results Ovid Healthstar
d Results
1 *Osteoporosis/ 19560 21737 1901 11099
2 osteoporos#s.tw. 34026 35796 1880 19752
3 bone loss$.tw. 14265 11657 315 8013
4 Bone Density/ 30978 29744 251 18825
5 (bone adj2 (density or fragil$)).tw. 26293 24729 753 15811
6 bone mass.tw. 10680 10257 178 5320
7 bmd.tw. 14102 13432 260 8703
8 exp Fractures, Bone/ 117949 119884 77165
9 Fracture$.tw. 138210 121797 1370 87072
10 Postmenopause/ 14361 27716 1238 12392
11 (post menopaus$ or postmenopaus$ or
post-menopaus$).tw.
36291 36928 2055 26297
12 Or/1-11 252732 230223 4698 155406
13 pharmacist.mp. or exp Pharmacists/ 11583 28008 29688 10896
14 exp Pharmacy/or pharmacy.mp. 43253 41432 57688 31208
15 or/13-14 48773 55457 70287 36175
16 12 and 15 277 402 292 214
17 limit 16 to English language 268 351 288 210
18 remove duplicates from 17 261 315 200 178
PubMed Search Terms (*Osteoporosis/OR Osteoporos OR Bone loss OR Bone Density/OR bone mass OR bmd OR exp Fractures, Bone/OR Fracture
OR Postmenopause/OR (post menopause or postmenopause or post-menopause)) AND (Pharmacists/OR pharmacist); Results: 118 articles
aOvid MEDLINE(R) (1950 to April Week 1 2010), OLDMEDLINE(R) (1947 to 1965), MEDLINE(R) Corrections, MEDLINE(R) In-Process &
Other Non-Indexed Citations (April 19 2010)
bEMBASE (1980 to 2010 week 15), EMBASE Classic (1947 to 1979)
cInternational Pharmaceutical Abstracts (1970 to April 2010)
dOvid Healthstar (1966 to March 2010)
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